UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)   October 10, 2006

                          MEDISCIENCE TECHNOLOGY CORP.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          NEW JERSEY                     0-7405                   22-1937826
--------------------------------------------------------------------------------
(State or other jurisdiction          (Commission               (IRS Employer
     of incorporation)                FileNumber)            Identification No.)

1235 Folkestone Way, P.O. Box 598, Cherry Hill, New Jersey             08034
--------------------------------------------------------------------------------
        (Address of principal executive offices)                     (Zip Code)

Registrant's telephone number, including area code (215) 485 0362

         (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2- below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17CFR240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13 e-4(c) under the
    Exchange Act (17 CFR 240.13 e-4(c))

<PAGE>

Item 8.01. Other Events.

CHERRY HILL, N.J. October 10 2006. Registrant  Mediscience  Technology Corp. has
agreed to provide $10,000 per month of seed funding  beginning  October 2, 2006.
for a period  of up to five  months  to  equity  partner  Infotonics  Technology
Center,  Inc.  of  Rochester  New  York to  accelerate  joint  progress  towards
commercialization  of  registrants  Optical  Biopsy Pill  through a "Newco" (NYS
subsidiary of Mediscience). Infotonics will use this initial Funding to hire and
assign a full-time  Commercialization  Program  Manage.  (CTO) to  continue  and
accelerate  Infotonics  efforts  on behalf on  Mediscience  to  achieve  product
commercialization success.
Registrants has additionally  contracted  commercialization  responsibility  and
oversight of its photonics technology IP platform to Infotonics who will develop
the  Mediscience  Optical  Fluorescence  IP platform  via two  initial  advanced
medical products, the Optical Biopsy Pill (OBP) and the CD Ratiometer (CDR).
The parties  expect that within this five months  period,  funding from a NYSTAR
TTIP grant award of $750,000  applied for by  Infotonics  plus, on completion of
registrants due diligence, the receipt by "Newco" of an initial $ 2-3M of bridge
funding from Empire  Financial Group Inc NY, should become available to continue
the product commercialization program.
(Submitted in full compliance with sections 8-K 1.01 and 2.01 re:  "materiality"
as applicable  and in fulfillment  of SEC Section 6, 6.01  Regulation  (FD) Full
Disclosure,  and  Section  7 and  7.0 as well as all  applicable  and  presently
effective Sarbanes-Oxley disclosure requirements under Regulation G).




Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Agreement dated September 28, 2006
99.1 Press Release of Mediscience Technology Corp. dated  October 10,2006



                                   SIGNATURES
Pursuant to the  requirements  of the  Securities  and Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized on

                                          MEDICSCIENCE TECHNOLOGY CORPORATION

                                          By:  Peter Katevatis
                                               ---------------------------------
                                               Name: Peter Katevatis
                                               Title: Chairman of the Board and

                                                                               2
<PAGE>


                                                      Chief Executive Officer
                                  Exhibit Index

Exhibit No.    Description
-----------    --------------------------------------------------------------
99.1           Agreement dated September 28, 2006
99.2           Press Release of Mediscience Technology Corp. dated



                                                                               3